HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caboodles

This article was originally published in The Rose Sheet

Executive Summary

Investment consultant Charles Beech tapped as acting CEO after agreeing to provide teen cosmetics brand with influx of capital during transition period, following departure of President Gary Schofield in May, Plano Molding Company division says. Additional higher level management staff may be hired in the near term, company adds. Caboodles is reportedly for sale...

You may also be interested in...



Caboodles Cosmetics

Sale of teen cosmetics line to private equity investment firm Pittco Capital Partners and select members of management is complete, the company announces. New capital will be used to add management, marketing and other resources to the firm, helping it to "reach its potential," Caboodles says. Investment consultant Charles Beech will serve as chairman and CEO of the new company. Experienced cosmetics exec, who has worked for Maybelline and Procter & Gamble, was tapped as acting CEO of Caboodles last year following the departure of Gary Schofield in May (1"The Rose Sheet" June 16, 2003, In Brief). Formerly owned by Plano Molding Company, the company also markets department store brands She She and C Me in addition to the mass market Caboodles line...

STADA Strengthens Specialty Partnership Role Via US Filing

STADA Strengthens Specialty Partnership Role Via US Filing

Qiagen’s Ambitions: Standing Alone & Strengthening Infectious Disease Portfolio

Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.

 

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel